Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study.

Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study.

Item
http://www.wikidata.org/entity/Q34340390
Trial WatchPazopanib in sarcomas: expanding the PALETTEPazopanib, a new therapy for metastatic soft tissue sarcomaCirculating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO).The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072.Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I studyA plasma cytokine and angiogenic factor (CAF) analysis for selection of bevacizumab therapy in patients with metastatic colorectal cancerSerum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and CilengitideTargeted therapy for soft tissue sarcomas in adolescents and young adults.The angiogenic asset of soft tissue sarcomas: a new tool to discover new therapeutic targets.Phosphoproteomics in translational research: a sarcoma perspective.Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized DosingElectrochemotherapy treatment of locally advanced and metastatic soft tissue sarcomas: results of a non-comparative phase II study.Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants.Positive response of a primary leiomyosarcoma of the breast following salvage hyperthermia and pazopanib.
P2860

Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study.

Item
http://www.wikidata.org/entity/Q34340390
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Cytokine and angiogenic factor ...... sarcoma: an EORTC-STBSG study.
@ast
Cytokine and angiogenic factor ...... sarcoma: an EORTC-STBSG study.
@en
Cytokine and angiogenic factor ...... sarcoma: an EORTC-STBSG study.
@nl
type
label
Cytokine and angiogenic factor ...... sarcoma: an EORTC-STBSG study.
@ast
Cytokine and angiogenic factor ...... sarcoma: an EORTC-STBSG study.
@en
Cytokine and angiogenic factor ...... sarcoma: an EORTC-STBSG study.
@nl
prefLabel
Cytokine and angiogenic factor ...... sarcoma: an EORTC-STBSG study.
@ast
Cytokine and angiogenic factor ...... sarcoma: an EORTC-STBSG study.
@en
Cytokine and angiogenic factor ...... sarcoma: an EORTC-STBSG study.
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P6179
P698
P932
P356
P1433
P1476
Cytokine and angiogenic factor ...... sarcoma: an EORTC-STBSG study.
@en
P2093
P2860
P2888
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P6179
P698
P932